Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases

NCT01963143 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

48

Enrollment

OTHER

Sponsor class

Conditions

Primary Immune Deficiency Disorders
Common Variable Immunodeficiency
X-linked Agammaglobulinaemia
Hyper-IgM Syndrome

Interventions

BIOLOGICAL: Gammaplex (5%)
BIOLOGICAL: Gammaplex 10

Sponsor

Bio Products Laboratory